ClinicalTrials.gg
RecruitingNCT06196203Updated Feb 11, 2025

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

A Phase 2 interventional study of AK117 and Placebo in Higher-risk Myelodysplastic Syndromes, sponsored by Akeso. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,363 studies in Myelodysplastic Syndromes with a site in United States — 174 open to participants now, 279 under way, 17 of them phase 3. Myelodysplastic Syndromes · United States.

Planned enrollment
250th of 1,189
90 · median 35
Started
2024
with 36 others
Phase 2
520 of 1,363
55 open now
Primary completion
2026-01
later than 53 of 275 live
Registered
1,274th of 1,363
by date

Among the 1,363 studies in Myelodysplastic Syndromes with a site in United States, this one is the 250th largest by planned enrollment of the 1,189 interventional ones that give a count, is one of 37 that started in 2024, is one of 520 in phase 2, reaches primary completion later than 53 of the 275 other live ones, and was the 1,274th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

174 of the 1,363 studies in Myelodysplastic Syndromes with a site in United States are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,363 studies in Myelodysplastic Syndromes with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).

03

Conditions studied

  • Higher-risk Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old at the time of enrolment.
  • (ECOG) performance status score of 0 to 2.
  • Expected ≥ 3 months.
  • Newly diagnosed HR-MDS, according to the 2016 World Health Organization (WHO) classification with the presence of \< 20% blasts in bone marrow or peripheral blood; Overall IPSS-R score ≥ 3.5.
  • Ability to undergo the study-required bone marrow sample collection procedures.
  • Suitable venous access for the study-required blood sampling (i.e., including PK and immunogenicity).
  • Female patients of childbearing age must have negative serum pregnancy test results before randomization or per region-specific guidance documented in the and a negative urine pregnancy test on the day of first dose prior to dosing.
  • Female patients of having sex with an unsterilized male partner must agree to use a highly effective method of from the beginning of screening until 180 days after the last dose of the study treatment.
  • Unsterilized male patients having sex with a female partner of childbearing potential must agree to use an effective method of contraception from the beginning of screening until 180 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • MDS evolving from a pre-existing myeloproliferative neoplasm (MPN), myelodysplastic/myeloproliferative neoplasms (MDS/MPN).
  • Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein alpha (SIRPα)-targeting agents.
  • Concurrently participating in another interventional clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  • Patients who previously diagnosed with another and have any evidence of residual disease.
  • Known allergy to any component of any study drug; known history of severe to other monoclonal antibodies.
  • Patients with any psychiatric or social factor which the investigator deems may interfere with the patient's ability to comply with the requirements of the study.
  • Patients with current hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy.
  • Patients with known cardiopulmonary disease defined as unstable angina, arrhythmia, congestive heart failure ( Class III or IV), decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders.
  • Patients who are breastfeeding or plans to breastfeed during the study.
  • Other conditions where the investigator considers the patient inappropriate for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    AK117 (dose 1) in combination with azacitidine

    Subjects receive AK117 (dose 1) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously

    Drug: AK117 · Drug: Azacitidine

  • Experimental
    AK117 (dose 2) in combination with azacitidine

    Subjects receive AK117 (dose 2) intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously

    Drug: AK117 · Drug: Azacitidine

  • Placebo comparator
    Placebo in combination with azacitidine

    Subjects receive placebo intravenously, in combination with azacitidine (75 mg/m2, D1-7, Q4W) subcutaneously

    Drug: Placebo · Drug: Azacitidine

Interventions

  • DrugAK117

    AK117 IV injection

  • DrugPlacebo

    Placebo IV injection

  • Azacitidine SC injection

06

What researchers measure

Primary outcomes

  1. Complete remission rate (CRR)

    CRR is defined as the proportion of subjects with complete remission (CR) per International Working Group (IWG) 2023 criteria

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Overall response rate (ORR)

    The proportion of subjects with recorded response per IWG 2023

    Time frame: Up to approximately 2 years

  2. Time to response (TTR)

    Time from the randomization to the first recorded response

    Time frame: Up to approximately 2 years

  3. Time to CR (TTCR)

    Time from the randomization to the first recorded CR

    Time frame: Up to approximately 2 years

  4. Duration of response (DoR)

    Time from the first recorded response until disease relapse or progression or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  5. Duration of CR (DoCR)

    Time from the first recorded CR until disease relapse or progression or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  6. Event-free survival (EFS)

    Time from randomization until transformation to AML or death due to any cause, whichever occurs first

    Time frame: Up to approximately 2 years

  7. Overall survival (OS)

    The time from randomization until death due to any cause

    Time frame: Up to approximately 2 years

  8. Number of subjects with adverse events (AEs)

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: Up to approximately 2 years

  9. Pharmacokinetic characteristics

    Serum concentrations of AK117 in individual subjects at different time points after AK117 administration

    Time frame: Up to approximately 2 years

  10. Anti-drug antibody (ADA)

    Number of subjects with detectable anti-drug antibodies

    Time frame: Up to approximately 2 years

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2026, 23 months after the start.

Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 23 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2023
First posted
Jan 9, 2024
StartActual
Feb 7, 2024
Primary completionEst.
Jan 2026
CompletionEst.
Jun 2026
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196203
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Feb 7, 2024
Primary completion
Jan 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 11, 2025

Study contacts

Wenting Li, MD
Contact
wenting01.li@akesobio.com
(+86)18116403289

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ligufalimab

Start the discussion